Table 2 Baseline characteristics of the parent RCT[23] participants (n = 42 children/adolescents)
Characteristic | Value |
|---|---|
Demographics | |
Age (yrs)* | 10.1 (3.8) |
Male/female (n) | 13/29 |
Body mass index* | 19.1 |
SDS BMI percentiles* | 64.5 (0.3) |
Disease duration (months)* | 46.9 (35.9) |
Pharmacological management | |
Analgesics: n (%) | 5 (12) |
NSAIDs: n (%) | 5 (12) |
Methotrexate: n (%) | 32 (76) |
Etanercept: n (%) | 12 (29) |
Sulphasalazine: n (%) | 1 (2) |
Rituximab: n (%) | 1 (2) |
Combination methotrexate & etanercept: n (%) | 10 (24) |
Disease subtypes | |
Persistent oligo: n (%) | 10 (24) |
Extended oligo: n (%) | 9 (21) |
Poly-: n (%) | 15 (36) |
Poly+: n (%) | 2 (5) |
PsA: n (%) | 3 (7) |
ERA: n (%) | 2 (5) |
Systemic: n (%) | 0 (0) |
Undifferentiated: n (%) | 1 (2) |